Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Agonist substance" patented technology

An agonist is a drug or an endogenous substance that binds to a Receptor (it has affinity for the receptor binding site) and produces a biological response (it possesses intrinsic activity).

Reagent for quantitative detection of Beta-receptor stimulant through Europium chelate latex time-resolved immunochromatographic assay

Disclosed is a reagent for quantitative detection of a Beta-receptor stimulant through Europium chelate latex time-resolved immunochromatographic assay. The reagent includes test card or test strip which includes a nitrocellulose membrane, absorbent paper, a sample pad and a PVC bottom plate, and a microporous container. A test sample firstly dissolves out Eu3+ fluorescent latex particles which are attached in the microporous container and marked with an anti-Beta-receptor-stimulant small-molecule antibody and after sufficient mixing, the test sample reacts completely with the marker and then a reaction liquid is dropped to the test card or test strip to carry out immunochromatography and at the same time, an immune competition reaction with a Beta-receptor-stimulant small molecule and BSA conjugate which envelopes the nitrocellulose membrane is carried out and five minutes later, the test card or the test strip is inserted into a fluorescent reading meter to measure a fluorescent value so as o obtain a test result. The method is high in sensitivity and quantitative and integrates the advantages of simple and convenient operation and rapidness, the method is applied to rapid detection of veterinary drug residuals such as the Beta-receptor stimulant and the like in food and raw materials on sites of production fields such as plantation, cultivation, animal husbandry and food processing and the like.
Owner:ROHI BIOTECH

Clenobuterol hydrochloride, salbutamol and paylean three joint inspection card and method for processing detecting sample

The invention relates to a clenobuterol hydrochloride, salbutamol and paylean three joint inspection card and a method for processing a detecting sample, and belongs to the technical field of detection of a beta-receptor stimulating agent, wherein a test strip is arranged inside a shell of the three joint inspection card, and the clenobuterol hydrochloride, salbutamol and paylean three joint inspection card is formed by the adhesion of a sample gasket, a colloidal gold membrane, a cellulose nitrate membrane and a water absorbing membrane to a bearing backboard in turn; the colloidal gold membrane is a glass fiber membrane of a colloidal gold marker containing a clenobuterol hydrochloride antibody, a salbutamol antibody and a paylean antibody; three detection strips are arranged on the cellulose nitrate membrane and contain clenobuterol hydrochloride protein conjugate, salbutamol protein conjugate and paylean protein conjugate respectively; and a quality control strip containing an anti-rabbit antibody or an anti-mouse antibody is arranged. The clenobuterol hydrochloride, salbutamol and paylean three joint inspection card has the advantages of simultaneously detecting the clenobuterol hydrochloride, the salbutamol and the paylean in urine or feed, animal tissue, meat and liver. The inspection card is easy to prepare and quick and convenient to use, saves the detection cost, and has accurate result.
Owner:无锡安迪生物工程有限公司

Indole derivatives

The invention relates to indole derivative having the general Formula Iwherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CH; Y represents CH2, O, S or SO2; R1 is H, (C1-4)-alkyl, (C1-4)alkyloxy, CN or halogen; R2, R2′, R3, R3′, R4, R4′, R5 and R5′ are independently hydrogen, (C1-4)alkyl (optionally substituted with OH) or CO—OR8; or one pair of geminal substituents R3 and R3′ or R5 and R5′ together represent a keto group, and the others are all hydrogen or (C1-4)alkyl; or R2 and R5 together represent a methylene or an ethylene bridge, and R2′, R3, R3′, R4, R4′ and R5′ are hydrogen; n is 1 or 2; R6 is H, (C1-4)alkyl (optionally substituted with OH, (C1-4)alkyloxy, CO—NR9R10, CO—OR11 or 1,2,4-oxadiazol-3-yl), SO2NR12R13 or COOR14; R7 is H or halogen; R8 is (C1-4)alkyl; R9 and R10 are independently hydrogen, (C1-4)alkyl or (C3-7)cycloalkyl, the alkyl groups being optionally substituted with OH or (C1-4)alkyloxy; R11 is H or (C1-4)alkyl; R12 and R13 are independently H or (C1-4)alkyl; R14 is (C1-6)alkyl; or a pharmaceutically acceptable salt thereof, as agonists of the cannabinoid CB1 receptor, which can be used in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.
Owner:MERCK SHARP & DOHME BV

High-throughput drug screening model using human pregnane X receptor (hPXR)-mediated dual-luciferase reporter gene technique

The invention discloses a high-throughput drug screening model using a human pregnane X receptor (hPXR)-mediated dual-luciferase reporter gene technique. The invention discloses a method for screening a human pregnane X receptor stimulant and an antagonist; by virtue of the method which is a new drug screening method, active drug ligands having regulating effect on a target gene, namely cytochrome CYP450 gene, of the PXR. A human embryonic renal HEK293T cell is subjected to the instantaneous co-transfection of an hPXR expression plasmid, a firefly luciferase reporter gene plasmid and an internal reference renilla luciferase plasmid by virtue of the method. The activities of the firefly luciferase and the renilla luciferase are simultaneously detected to show the regulating effect of the drug on the PXR activity, so as to establish a method for screening the hPXR stimulant and the hPXR antagonist. On one hand, the method can screen out compounds having an hPXR stimulating activity at high throughput from a massive compound library so as to avoid a risk that adverse drugs interact caused by the combined use of new drugs; and on the other hand, the method can screen out compounds having PXR antagonistic activity to inhibit the inducing effect of ligands on drug metabolic enzyme and transporter, so as to reduce the occurrence of adverse DDI and to reverse the drug resistance of anticancer drugs.
Owner:SUN YAT SEN UNIV

Method for measuring the modulation of the activation of a g protein-coupled receptor with gtp analogues

The invention relates to a method for determining the ability of a molecule to modulate the activation of a G protein-coupled receptor (GPCR), said method comprising the following steps:
    • a) introducing, in a first container:
      • a membrane preparation bearing one or more GPCRs and one or more alpha G-proteins,
      • a source of nonhydrolyzable or slowly hydrolyzable GTP labeled with a first member of a pair of RET partners,
      • a ligand of the alpha subunit of a G protein (alpha G-protein) labeled with a second member of the pair of RET partners, said ligand being capable of binding to the full alpha G-protein bound to the nonhydrolyzable or slowly hydrolyzable GTP labeled with the first member of a pair of RET partners,
      • optionally a GPCR agonist;
    • b) measuring the RET signal emitted in the first container;
    • c) introducing (i) in a second container, the same reagents as in step a) and the molecule to be assayed or (ii) in the first container, the molecule to be assayed;
    • d) measuring the RET signal emitted in the second container or in the first container obtained in step c);
    • e) comparing the signals obtained in steps b) and d), a modulation of the signal obtained in step d) relative to that obtained in step b) indicating that the molecule to be tested is capable of modulating the activation of the GPCR.
Owner:CISBIO BIOASSAYS +1

Hematopoietic stem cell proliferation and preparation method

The present invention relates to a hematopoietic stem cell proliferation and preparation method, the method includes that hematopoietic stem cells are activated by stimulating mononuclear cells contained with a CD52 agonist, stimulating the mononuclear cells are stimulated in a culture medium in which the concentration of the CD52 agonist is 15 [mu] g / ml or less, and telomerase is added to the culture medium at the same time, the telomerase is extracted from broccoli telomerase extract, broccoli buds are put into a mortar, liquid nitrogen is added, the broccoli buds are ground into powder, an extracting solution is added, grinding continues to be conducted for 10-20 min, the powder is transferred into a centrifugal tube to be centrifuged for 15-20 min after grinding, supernate is subpackaged into EP tubes, PEG 6000 is added into the EP tubes, oscillation mixing is conducted for 40-60 min at the constant temperature of 4-7 DEG C, centrifugation is conducted for 2-4 min at the temperature of 4-7 DEG C, supernate is removed, the lower-layer substance is stored at -80 DEG C to obtain the broccoli telomerase extract. According to the hematopoietic stem cell proliferation and preparation method, the telomerase is added into the culture medium, the telomerase technology is applied to hematopoietic stem cell proliferation, the proliferation speed of hematopoietic stem cells can be increased by adding the telomerase, and the proliferation efficiency is improved.
Owner:赵彬
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products